The overall goal of the Formulation Development Core (Core C) is to provide preformulation data, formulation development efforts, and formulation assessment evaluations in support of Projects 1, 2, and 3. In addition the Core will coordinate and oversee manufacture, release, and stability assessment of all GMP supplies to be used in the proposed clinical trials in Project 3. Finally Core C will develop prototype formulations with alternate combinations identified in Project 1 and biologically relevant methods for assessment of rectal microbicide product. Given the significant anatomical and physiological differences in the rectal and vaginal compartments it is essential to design rectal specific microbicide products to effectively inhibit rectal transmission of HIV. Formulation strategies within the scope of Core activities will focus on two hypothesis centered on gel like semisolid dosage forms or enema like liquid dosage forms. Quantitative assays have been developed in the laboratory for both UC781 and TFV. These assays will be used throughout the development process. Once prototype formulations have been developed they will be evaluated for toxicity and bioactivity in Project 1. This data will be used to choose the optimal products for advancement. The optimal products will be scaled up and R&D quality material manufactured for analysis in the mouse efficacy model in Project 2. The core will continually monitor product mechanical and chemical characteristics throughout the development process. Manufacture of GMP quality material will be achieved through a contract research lab with extensive experience with manufacture of GMP quality semisolid systems. The Core will be responsible for methods transfer, development and sign off of batch records generated, assist in protocol development for product assessment methods established for GMP product release, oversee GMP batch manufacture, and review stability results obtained. Three GMP batches will be manufactured (UC781 only, TFV only, and combination). Another important outcome from the core will be the development of biologically relevant product assessment evaluations for rectal products given the current lack of such methods. The core will directly support Projects 1, 2, and 3 of this grant proposal.

Public Health Relevance

Due to anatomical and physiological differences in the vaginal and rectal compartments, vaginal products will most likely not be adequately effective for protection from rectal transmission of HIV. The Formulation Development Core (Core C) has a set of objectives focused on the development of rectal specific microbicide products for delivery of tenofovir (TFV), UC781, and a combination of these two active agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082637-05
Application #
8722093
Study Section
Special Emphasis Panel (ZAI1-BP-A (J1))
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$193,893
Indirect Cost
$22,354
Name
Magee-Women's Research Institute and Foundation
Department
Type
DUNS #
119132785
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Dezzutti, Charlene S; Russo, Julie; Wang, Lin et al. (2014) Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation. PLoS One 9:e102585
McGowan, Ian (2014) The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv 11:69-82
Wahl, Angela; Victor Garcia, J (2014) The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract. J Immunol Methods 410:28-33
Chateau, Morgan L; Denton, Paul W; Swanson, Michael D et al. (2013) Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One 8:e60024
Nochi, Tomonori; Denton, Paul W; Wahl, Angela et al. (2013) Cryptopatches are essential for the development of human GALT. Cell Rep 3:1874-84
Chateau, Morgan; Swanson, Michael D; Garcia, J Victor (2013) Inefficient vaginal transmission of tenofovir-resistant HIV-1. J Virol 87:1274-7
Denton, Paul W; Olesen, Rikke; Choudhary, Shailesh K et al. (2012) Generation of HIV latency in humanized BLT mice. J Virol 86:630-4
Anton, Peter A (2012) Future prospects and perspectives on microbicides. Curr HIV Res 10:113-5
Goldsmith, Jeff; Caffo, Brian; Crainiceanu, Ciprian et al. (2011) NONLINEAR TUBE-FITTING FOR THE ANALYSIS OF ANATOMICAL AND FUNCTIONAL STRUCTURES. Ann Appl Stat 5:337-363
Anton, Peter; Herold, Betsy C (2011) HIV transmission: time for translational studies to bridge the gap. Sci Transl Med 3:77ps11

Showing the most recent 10 out of 13 publications